What is METXF?
, a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 88.65M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.